Antipyretic analgesics generally exhibit potent antipyretic, analgesic and anti‑inflammatory effects.Their anti‑inflammatory mechanism differs from that of glucocorticoids, so they are also known as non‑steroidal anti‑inflammatory drugs (NSAIDs), which are widely used worldwide.
Ibuprofen is an arylpropionic acid antipyretic analgesic and one of the major antipyretic and analgesic APIs exported from China.Since the 1980s, with the expiration of relevant global patents on ibuprofen, a number of Chinese enterprises have begun to develop and produce ibuprofen.
After decades of process improvement and market consolidation, China has become one of the world's leading producers and exporters of ibuprofen APIs.Among the world's top five ibuprofen API manufacturers, two are from China:Shandong Xinhua Pharmaceutical and Hubei Hengdi Pharmaceutical.
1.Period of Fluctuations in Export Value
In 2011, China's export value of ibuprofen APIs stood at US$52 million, with an export volume of 5,024.82 tonnes.In 2022, the export value reached US$101 million, with an export volume of 7,160.6 tonnes.
Over the 12-year period, China's cumulative growth in ibuprofen API export value was 95.89%,and the cumulative growth in export volume was 42.50%.The overall export value showed an upward trend,but the growth rate of export volume was lower than that of export value.As a bulk API, ibuprofen still showed a pattern of exchanging volume for price in exports over the decade.
From 2011 to 2013,China's ibuprofen API export value and volume grew steadily,while prices remained depressed, fluctuating around US$10 per kilogram.
In the following years,affected by the international trade environment and RMB appreciation,prices of various basic production factors rose.However, as a traditional bulk API with low added value,ibuprofen struggled to break through,which was reflected in declines in both actual export volume and export value.
2.Period of Simultaneous Rise in Export Volume and Price
In June 2018, BASF (Germany) suspended its ibuprofen API production line for technical rectification due to technical problems, resulting in a reduction in effective market supply.The ibuprofen API capacity reduced by BASF accounted for approximately 20% of the global total capacity.Against this backdrop, China's ibuprofen API exports ushered in a window of growth.
In 2018, the average export price of ibuprofen APIs broke the "US$10 ceiling" that had persisted for many years, reaching US$16.42 per kg for the whole year.It rose further to US$19.83 per kg in 2019, with the peak hitting US$22.9 per kg in April 2019.
Along with rising prices, export volume continued to expand.Compared with 2016, export volume in 2019 increased by 20.43%, while export value surged by more than 100%, achieving a doubling in growth.
Since 2015, the former China Food and Drug Administration (CFDA) had launched a series of regulatory reforms, including API-related review and approval and the consistency evaluation for generic drugs.The increased compliance costs for enterprises indirectly drove up the price of ibuprofen APIs.
In 2015, the newly revised Environmental Protection Law came into force,significantly increasing penalties for polluting enterprises.The synthesis of ibuprofen APIs relies on petroleum as raw material,and the production process involves many energy-intensive steps.Under strict environmental pressure,more API factories were suspended or subject to production restrictions,which was also one of the reasons for the consecutive declines in export value and volume in 2014 and 2015.
3.Period of Adjustment amid Volatile Changes
At the end of 2019, the COVID-19 pandemic struck unexpectedly. In the early stage of the pandemic, understanding of COVID-19 was relatively limited across countries. Based on a research paper published in The Lancet, the WHO issued an advisory in March 2020 suggesting that ibuprofen might aggravate COVID-19 symptoms and recommending cautious use of ibuprofen. Although the WHO quickly corrected the statement, clarifying that it did not oppose the use of ibuprofen for COVID-19 treatment, the widely circulated public opinion still caused a slump in China's ibuprofen API exports.
Coupled with the impact of the pandemic at home, part of China's production capacity was not fully released. Meanwhile, BASF's ibuprofen plant in Germany gradually resumed production and restored its original capacity. As a result, while China's ibuprofen API export volume only declined slightly, the unit export price plummeted, leading to a notable drop in export value in 2020.
In 2021, China achieved remarkable progress in epidemic prevention and control, and factories resumed production smoothly. International anti-pandemic demand rose significantly. Furthermore, starting from March 20, 2020, the Ministry of Finance raised the export tax rebate rate for products including ibuprofen to 13%. Consequently, China's ibuprofen API export volume remained relatively stable in 2020–2021, but export prices fell sharply compared with pre-pandemic levels, pushing the 2021 export value below the level of the same period in 2018.
Since 2022, as countries adjusted their COVID-19 prevention and control policies, global demand for ibuprofen APIs has declined. In addition, affected by the crowding-out effect from exports of other antipyretic analgesics such as paracetamol, both the export volume and export value of ibuprofen APIs further decreased. As shown in Figure 3, except for August 2022, monthly exports of paracetamol APIs maintained year-on-year growth for the rest of 2022, with an annual export volume of 46,699.95 tonnes, representing a year-on-year increase of 25.51%.
Moreover, China adjusted its epidemic prevention and control measures in November 2022. From October to December 2022, China's ibuprofen API exports posted three consecutive months of month-on-month decline. On the one hand, repeated COVID-19 outbreaks disrupted enterprise production; on the other hand, a sudden surge in domestic demand prompted API manufacturers to reduce exports and redirect supplies to domestic preparation enterprises.
Accordingly, paracetamol, another classic antipyretic analgesic, also saw a drop in export volume in the last two months of 2022, reversing the growth trend seen in the first 10 months. This indirectly reflects that exports of antipyretic analgesics were reduced to meet domestic anti-pandemic demand during the special period. Figure 4 illustrates the monthly export value and month-on-month growth of China's ibuprofen APIs in 2022.
Observation of ibuprofen API export prices over the past two years shows that they have remained relatively stable at around US$14 per kilogram, with a certain downward trend.
It should be noted that the average export price of ibuprofen APIs since 2021 has been supported by a combination of factors: the resumption of production by foreign competitors, as well as rising costs related to pandemic control, supply chains, shipping and logistics, and raw material prices during the epidemic.
As the impact of the epidemic on social activities gradually eases and a number of COVID-19 specific drugs are launched successively, production capacity can be fully released while corresponding demand weakens.It is expected that the unit export price of ibuprofen APIs will be unlikely to rise sharply again in the future, and the price outlook will be not optimistic.
Conclusion
An analysis of the historical situation since 2011 shows that prices of ibuprofen APIs are largely driven by supply-side factors, while the pull effect from the demand side is relatively limited. China's exports of ibuprofen APIs have gone through three phases: a period of short-term fluctuations, a phase of simultaneous growth in volume and price, and a period of structural adjustment amid complex conditions.
As a window of rising overseas demand and falling global total capacity, 2018 marked a golden period of growth for China's ibuprofen API exports. Anti-pandemic demand since the outbreak of COVID-19 has also played a certain role in stabilizing export volumes. However, given weakening global anti-pandemic demand and sufficient international production capacity in 2023, both the export volume and export value of ibuprofen APIs are expected to decline further.
Against the backdrop of China's strong promotion of green transformation, technological innovation and industrial upgrading in the API industry, and with the development of the downstream preparation sector, high value-added specialty APIs and the CDMO model will become the direction of high-quality industry development. As a traditional bulk API, ibuprofen may break away from the long-standing development model of "exchanging volume for price" and must face the reality of partial capacity relocation.
Source: China Pharmaceuticals












